Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

Fig. 2

CONSORT diagram illustrating participant flow. Since this was a crossover trial and every patient was supposed to receive three treatments, the total number of patients is not the sum of the number of each patient on each treatment. Of the seven patients who discontinued prematurely, the most frequent reason was non-compliance with the trial protocol (three patients). BID: twice daily; QD: once daily; AE: adverse event

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us